NASDAQ:VYGR

Voyager Therapeutics (VYGR) Stock Price, News & Analysis

Voyager Therapeutics logo
$4.23 -0.15 (-3.42%)
Closing price 02/14/2025 04:00 PM Eastern
Extended Trading
$4.24 +0.00 (+0.12%)
As of 02/14/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Voyager Therapeutics Stock (NASDAQ:VYGR)

Key Stats

Today's Range
$4.20
$4.60
50-Day Range
$4.20
$6.48
52-Week Range
$4.00
$10.66
Volume
441,402 shs
Average Volume
310,971 shs
Market Capitalization
$231.08 million
P/E Ratio
5.96
Dividend Yield
N/A
Price Target
$15.72
Consensus Rating
Buy

Company Overview

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Voyager Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
92nd Percentile Overall Score

VYGR MarketRank™: 

Voyager Therapeutics scored higher than 92% of companies evaluated by MarketBeat, and ranked 89th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Voyager Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Voyager Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Voyager Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Voyager Therapeutics are expected to decrease in the coming year, from ($0.91) to ($1.58) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Voyager Therapeutics is 5.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.39.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Voyager Therapeutics is 5.96, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.20.

  • Price to Book Value per Share Ratio

    Voyager Therapeutics has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Voyager Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    4.78% of the outstanding shares of Voyager Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Voyager Therapeutics has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in Voyager Therapeutics has recently increased by 2.35%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Voyager Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Voyager Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.78% of the outstanding shares of Voyager Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Voyager Therapeutics has a short interest ratio ("days to cover") of 5.9.
  • Change versus previous month

    Short interest in Voyager Therapeutics has recently increased by 2.35%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Voyager Therapeutics has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 23 news articles for Voyager Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    10 people have searched for VYGR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Voyager Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $58,548.00 in company stock.

  • Percentage Held by Insiders

    Only 4.53% of the stock of Voyager Therapeutics is held by insiders.

  • Percentage Held by Institutions

    48.03% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Voyager Therapeutics' insider trading history.
Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VYGR Stock News Headlines

Wedbush Has Pessimistic Outlook of VYGR FY2025 Earnings
Market down? Do this now.
During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.
Voyager Therapeutics price target lowered to $12 from $14 at Wells Fargo
See More Headlines

VYGR Stock Analysis - Frequently Asked Questions

Voyager Therapeutics' stock was trading at $5.67 at the beginning of the year. Since then, VYGR shares have decreased by 25.4% and is now trading at $4.23.
View the best growth stocks for 2025 here
.

Voyager Therapeutics, Inc. (NASDAQ:VYGR) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.29. The business earned $24.63 million during the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a trailing twelve-month return on equity of 8.33%.

Top institutional investors of Voyager Therapeutics include Vanguard Group Inc. (5.89%), Farallon Capital Management LLC (4.71%), Dimensional Fund Advisors LP (2.53%) and Geode Capital Management LLC (1.98%). Insiders that own company stock include Neurocrine Biosciences Inc, Rock Ventures Iii LP Third, Ecor1 Capital, Llc, Robin Swartz, Robert W Hesslein, Todd Alfred Carter, Sandell Jacquelyn Fahey and Glenn Pierce.
View institutional ownership trends
.

Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Voyager Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AUO (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
11/12/2024
Today
2/17/2025
Next Earnings (Estimated)
2/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VYGR
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.72
High Stock Price Target
$30.00
Low Stock Price Target
$5.73
Potential Upside/Downside
+271.5%
Consensus Rating
Buy
Rating Score (0-4)
3.11
Research Coverage
9 Analysts

Profitability

Net Income
$132.33 million
Pretax Margin
16.35%

Debt

Sales & Book Value

Annual Sales
$250.01 million
Cash Flow
$2.29 per share
Book Value
$5.37 per share

Miscellaneous

Free Float
52,151,000
Market Cap
$231.08 million
Optionable
Optionable
Beta
0.91

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:VYGR) was last updated on 2/17/2025 by MarketBeat.com Staff
From Our Partners